Ventilator-Associated Pneumonia Market Research Report - Forecast till 2027

Ventilator-Associated Pneumonia Market Research Report: Information by Diagnosis (Clinical, Radiological, Microbiological), End User (Hospitals & Clinics, Research & Academic Institutes, Ambulatory Care Centers), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0868-HCR | February 2021 | Region: Global | 110 Pages         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

 

6. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS

6.1. Overview

6.2. Clinical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Radiological

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Microbiological

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1. Blood and pleural fluid cultures

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2. Nonquantitative or semi quantitative airway sampling

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.3. Quantitative cultures of airway specimens

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Ambulatory Care Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Ventilator-Associated Pneumonia Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Ventilator-Associated Pneumonia Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2020

9.8.2. Major Players R&D Expenditure 2020

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Adenium Biotech ApS

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Merck & Co., Inc.

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. AstraZeneca

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. MedImmune

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Nabriva Therapeutics AG

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Thermo Fisher Scientific

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Bayer AG

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Wockhardt

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Shionogi Inc.

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Cardeas Pharma

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Others

11. APPENDIX

11.1. References

11.2. Related Reports

 

LIST OF TABLES

TABLE 1 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 6 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 US: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 9 US: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 CANADA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 11 CANADA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 LATIN AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 13 LATIN AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 14 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 15 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET, BY END USER, 2020-2027 (USD MILLION)

 

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET

FIGURE 4 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY DIAGNOSIS, 2020 (%)

FIGURE 5 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY END USER, 2020 (%)

FIGURE 6 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 8 EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 WESTERN EUROPE: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 ASIA-PACIFIC: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 MIDDLE EAST & AFRICA: VENTILATOR-ASSOCIATED PNEUMONIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 ADENIUM BIOTECH APS.: KEY FINANCIALS

FIGURE 14 ADENIUM BIOTECH APS: SEGMENTAL REVENUE

FIGURE 15 ADENIUM BIOTECH APS: REGIONAL REVENUE

FIGURE 16 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 17 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 18 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 19 ASTRAZENECA: KEY FINANCIALS

FIGURE 20 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 21 ASTRAZENECA: REGIONAL REVENUE

FIGURE 22 MEDIMMUNE: KEY FINANCIALS

FIGURE 23 MEDIMMUNE: SEGMENTAL REVENUE

FIGURE 24 MEDIMMUNE: REGIONAL REVENUE

FIGURE 25 NABRIVA THERAPEUTICS AG: KEY FINANCIALS

FIGURE 26 NABRIVA THERAPEUTICS AG: SEGMENTAL REVENUE

FIGURE 27 NABRIVA THERAPEUTICS AG: REGIONAL REVENUE

FIGURE 28 THERMO FISHER SCIENTIFIC: KEY FINANCIALS

FIGURE 29 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE

FIGURE 30 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE

FIGURE 31 BAYER AG: KEY FINANCIALS

FIGURE 32 BAYER AG: SEGMENTAL REVENUE

FIGURE 33 BAYER AG: REGIONAL REVENUE

FIGURE 34 WOCKHARDT: KEY FINANCIALS

FIGURE 35 WOCKHARDT: SEGMENTAL REVENUE

FIGURE 36 WOCKHARDT: REGIONAL REVENUE

FIGURE 37 SHIONOGI INC.: KEY FINANCIALS

FIGURE 38 SHIONOGI INC.: SEGMENTAL REVENUE

FIGURE 39 SHIONOGI INC.: REGIONAL REVENUE

FIGURE 40 CARDEAS PHARMA: KEY FINANCIALS

FIGURE 41 CARDEAS PHARMA: SEGMENTAL REVENUE

FIGURE 42 CARDEAS PHARMA: REGIONAL REVENUE

Ventilator-Associated Pneumonia Market

The ventilator-associated pneumonia market was valued USD 988.92 million at a CAGR 10.24% by 2030

Segmentation

by Diagnosis Clinical Radiological Microbiological
By End User Hospitals & Clinics Research & Academic Institutes Ambulatory Care Centers

Key Players

  • Adenium Biotech ApS of Denmark
  • Crdeas Pharma of the United States
  • Merck and CO. Inc. of the United States
  • Shinogi Inc. of Japan
  • AstraZeneca of the United Kingdom

Drivers

  • Growing prevalence of ventilator-associated pneumonia
  • Increasing incidences of traumatic brain injury
Speak to Analyst Request a Free Sample

Ventilator-Associated Pneumonia Market Overview


The ventilator-associated pneumonia market was valued USD of 968.92 million in 2018 and expected to grow at a CAGR value of about 9.45% during the forecast period. This particular type of disorder especially affects the lungs that are on ventilators. This type of disorder is caused due to the person suffering from trauma, lung disorder, and some kind of neurological disease. As per the report so published by the National Centre for Biotechnology Information (NCBI) in the year November 2017, the rise in ventilator suffering people ranges from 5% to 67%. After the incubation of the patient pulmonary disease has been increased to a wide extent. Treatment of VAP has been planned as per oxygenation, temperature, count of blood leukocyte, pulmonary radiography, and many more.


The ventilator-associated pneumonia market is anticipated to expand at a rapid rate in the upcoming future. Here the infected air passes through the endotracheal tube containing microorganisms. These microorganisms are passed to the lungs thus leading to respiratory distress. The VAP vaccines are very much important for patients in hospitals or the ones having compromised immune systems. The VAP is estimated to range from 2.13 to 116 per thousand each day.


COVID 19 ANALYSIS


The outburst of COVID led to the disruption in the manufacturing units. The production process from the industry was hampered. The outbreak of the pandemic brought a downfall in the economic conditions affecting the growth of the market. A declination in consumer behavior was marked. Supply chain analysis was being interrupted. The government took several necessary steps for protecting the people from COVID.


Ventilator-Associated Pneumonia Market Dynamics


Drivers


Some of the driving factors like growth in prevalence of certain ventilator diseases and rise in traumatic brain injuries helps in pushing up the market size and helps in its development Crdeas Pharma of the United States. The rise in the development of research activities and the increase in expenses for the development of efficient treatment methods for the disorder helps in spurring up the ventilator-associated pneumonia market growth. Due to the unmet needs of the rising patent population the chances for expansion increase.


Opportunities


Some of the patients suffering from VAP have helped in rising up ICU hospitalization. Reintubation disorder, age, and some of the altered consciousness suffering from VAP and rise in mechanical ventilation along with supine position have created an opportunity for ventilator-associated pneumonia market development. The need for optical biotic treatment has risen the opportunity for market size. Adoption of reimbursement policies, adopting different technological advancement, and increase in funding ability has raised the opportunity for market growth. A rise in awareness about the disease improves growth.


Challenges


The growth of the market is especially affected by the infections from the hospital patients especially ICU patients becomes the most important Challenging factor for ventilator-associated pneumonia market growth. People undergoing glucocorticoid therapy or one suffering from diabetes mellitus affect the growth and market size challenging the market. The presence of limited health resources becomes a challenging factor for the improvement of growth. Underestimation of those health resources deteriorates the growth rate.


Restraints


Some of the restraining factors like spending too much on diagnostic tests, increase in charges for ventilator purposes along incorrect reimbursement scenarios will have a negative impact on ventilator-associated pneumonia market size. Some of the side effects associated with the treatment have restrained the market size. Lack of the improvement of reimbursement policies has deprived the market expansion and its growth.


Ventilator-Associated Pneumonia Market Segmentation


The ventilator-associated pneumonia market trends it has been found that the market has been classified based on diagnosis, end-users, and also based on region.


As per the diagnosis segment, the pneumonia market is being divided into a clinical segment, radiology segment, microbiological, and many more. Moreover, the microbiological segment is being bifurcated into quantitative cultures for the specimens related to airways, cultures on blood and pleural fluid, sampling of non-quantitative and semi-quantitative cultures.


As per the end-user segment it has been found that the market has been classified into research and some of the academic institutions, hospitals and medical centers, care units of ambulatory sectors, and many more.


Based on region, the market has been divided into the North American region, Latin American region. Some of the North American markets are further classified into the regions of the United States and some of the Canadian regions. Moreover, the European market covers major ventilator-associated pneumonia market share into Western Europe and Eastern Europe. The Western European market includes France, Spain, Italy, Germany, and some of the regions of the Western European region. On a regional basis, the Asia Pacific market has extended its business into the Middle East and African region. From the ventilator-associated pneumonia market outlook, it was marked that the ambulatory surgical center is being adopted to prevent the growth of microorganisms.


Technology helped in the detection of causative bacteria according to which the VAP is being denoted. The advancement of technology led to the recognition of specific bacteria. Causing respiratory disease. Technology-led to the setting up of more research institutions and labs for developing and launching innovative products. The growing technology has provided fact-based solutions to the key players.


Ventilator-Associated Pneumonia Market Regional Analysis


Regionally and geographically, from the ventilator-associated pneumonia market outlook, it was marked about the differentiation abut the market region into American region, some of the European region, Asia-Pacific along with the Middle East and African region. The United States plays a dominating role thus owing to the presence of pneumatic cases along with the rise in government initiatives along with the funds of certain non-governmental institutions for controlling the spread of disease. The European region holds the second largest ventilator-associated pneumonia market share due to the presence of certain patent populations who have lung problems and the presence of certain healthcare industries helps in driving up the market size. Moreover, the Asia Pacific region has been marked to be the largest and fastest-growing region due to the prevalence of certain infectious diseases and the presence of ventilator-associated pneumatic people.


Ventilator-Associated Pneumonia Market Competitive Landscape


Some of the key players operating in the market are Adenium Biotech ApS of Denmark, Crdeas Pharma of the United States, Merck and CO. Inc. of the United States, Shinogi Inc. of Japan, AstraZeneca of the United Kingdom, Wockhardt of the Indian region, MedImmune of the United States, Thermo Fischer Scientific of the United States, Nabriva Therapeutics  AG of Ireland and many more. These key players played a major role in building partnerships, collaborating, acquisitions, joint ventures and carried out some of the strategic analyses for playing a major role in improvement.


By taking the help of strategic analysis they carry out trending innovative procedures and manufacture the ventilators. It symbolizes and gives a neutral perspective about the industrial trends and their developments. It gives ideas about the potential and niche market segments and the regions exhibiting some of the promising ventilator associated pneumonia market growth. It gives ideas about the historical, current, and projected market structure in terms of market value and volume. These comprehensive market players offers products, and carryout certain recent developments, SWOT analysis, and some of the competitive strategies by certain key players.


Ventilator-Associated Pneumonia Market Report Overview


From the report analysis, it was found about the market drivers playing a major role in improving the growth. It signifies the growth opportunities along with the challenging factors and restraining factor that contributes to the factor affecting the strengthening position in the market. The report gives an in-depth analysis of the market segmentation. It highlights the manufacturing of innovative products from the manufacturing units.


It gives a close watch about the market share so occupied by various key players. It gives a clear overview and a geographical analysis of the market scenario and its developing structure during the ventilator-associated pneumonia market forecast period. It gives a plethora of qualitative and quantitative research and also includes the demand and supply forces that have an influential role in the market. The report gives descriptions of microbiological evidence, mortality rate, and incidence rate.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 968.92 Million
  • 2027: Significant Value
  •   CAGR   9.45% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Diagnosis and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Ireland), Thermo Fisher Scientific (US), Bayer AG (Germany), Wockhardt (India), Shionogi Inc. (Japan), Cardeas Pharma (US)
      Key Market Opportunities    increasing research and development expenditure for the development of effective treatment for the disease
      Key Market Drivers

  • growing prevalence of ventilator-associated pneumonia
  • increasing incidences of traumatic brain injury


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation of the ventilator-associated pneumonia market had reached USD 968.92 MN in 2018.

    Diagnosisis projected to grow at 9.45% CAGR during the assessment period (2019-2025).

    Increasing incidences of traumatic brain injury and increasing R&D expenditure for the development of effective treatment for the disease are the major tailwinds pushing the growth of the Ventilator-Associated Pneumonia Market.

    North America holds the largest share in the Ventilator-Associated Pneumonia Market, followed by Europe and the Asia Pacific, respectively.

    Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca (UK), Nabriva Therapeutics AG (Austria), and MedImmune (US), are some of the major players operating in the ventilator-associated pneumonia market.